T1	Competing_trial 0 321	Patient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study (where Incyte can delegate the sponsorship to a preferred CRO, if applicable) that is approved to enroll into this rollover study, is receiving ruxolitinib and has fulfilled all of the requirements of the parent protocol.
T2	Drug 379 390	ruxolitinib
T3	Non-query-able 323 425	Patient is currently benefiting from the treatment with ruxolitinib, as determined by the investigator
T4	Post-eligibility 427 644	Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures
T5	Condition 683 702	progressive disease
T6	Drug 773 784	ruxolitinib
T7	Informed_consent 786 1021	Written informed consent obtained prior to enrolling in roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness
